Poster Session D - Tuesday Morning
Category: IBD
John Galatowitsch, MD
University of Colorado School of Medicine
Aurora, CO
Ustekinumab | Tofacitinib | |
PATIENTS | 30 | 30 |
AGE | ||
Median, Years | 42.5 | 38.5 |
IQR, Years | 32.5 - 55.0 | 29.0 - 46.5 |
SEX | ||
Male, Percent | 50.0 | 56.0 |
Female, Percent | 50.0 | 44.0 |
RACE | ||
White, Percent | 86.7 | 93.3 |
Asian, Percent | 3.3 | 0.0 |
More Than One Race, Percent | 3.3 | 3.3 |
Unknown Race, Percent | 6.7 | 3.3 |
ETHNICITY | ||
Hispanic or Latino, Percent | 10.0 | 6.7 |
DISEASE DURATION | ||
Median, Years | 6.0 | 6.0 |
IQR, Years | 3.3 - 11.0 | 4.0 - 9.8 |
DISEASE DISTRIBUTION | ||
Extensive Colitis (E3), Percent | 63.3 | 83.3 |
Left-Sided Colitis (E2), Percent | 36.7 | 16.7 |
Proctosigmoiditis (E1), Percent | 0.0 | 0.0 |
SMOKING STATUS | ||
Active Smoker, Percent | 0.0 | 0.0 |
PRIOR FAILED THERAPIES | ||
Mean Number of Failed Biologic Therapies | 2.3 | 3.2 |
Failed 1 Biologic, Percent | 53.3 | 20.0 |
Failed 2 Biologics, Percent | 36.7 | 46.7 |
Failed 3+ Biologics, Percent | 10.0 | 33.3 |
Failed TNF Inhibitor, Percent | 76.7 | 96.7 |
Failed Vedolizumab, Percent | 63.3 | 73.3 |
Failed Immunosuppressant, Percent | 66.7 | 80.0 |
BASELINE PARTIAL MAYO SCORE | ||
Median | 4.0 | 5.5 |
IQR | 3.0 - 6.0 | 4.0 - 7.0 |
Baseline Rectal Bleeding, Percent | 43.8 | 73.3 |
BASELINE INFLAMMATORY DATA | ||
CRP, Mean | 11.1 | 12.9 |
CRP, StDev | 16.0 | 14.5 |
Fecal Calprotectin, Mean | 1546 | 1048 |
Fecal Calprotectin, StDev | 1373 | 1121 |
BASELINE STEROID USE | ||
Steroid Utilization, Percent | 60.0 | 76.7 |
Prednisone Utilization, Percent | 36.7 | 70.0 |
Budesonide Utilization, Percent | 16.7 | 3.3 |
BASELINE NON-BIOLOGIC THERAPIES | ||
Immunosuppressant Utilization, Percent | 3.3 | 3.3 |
Aminosalicylate Utilization, Percent | 10.0 | 10.0 |